Bangkok Dusit Medical Services Public Co. Ltd.

As of June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR carries a market capitalization of 306.72B, placing it among publicly traded companies globally. Its enterprise value stands at 325.12B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Bangkok Dusit Medical Services Public Co. Ltd. NVDR's next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR has 15.89B shares outstanding.

As of June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR trades at a trailing price-to-earnings ratio of 20.02. The price-to-sales ratio is 2.74, and the price-to-book ratio stands at 2.97.

As of June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR trades at an EV/EBITDA multiple of 12.14 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.91 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Bangkok Dusit Medical Services Public Co. Ltd. NVDR trades at an EV/FCF ratio of 26.70, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 325.12B versus a market cap of 306.72B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 17.79, indicating elevated leverage, while an interest coverage ratio of 84.22 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR posted a return on equity (ROE) of 14.96, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.74 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.91, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.16, useful for judging operating efficiency across full business cycles. The company generates approximately 3.08M in revenue per employee across its workforce of 36,252.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 21.12 indicates how many times Bangkok Dusit Medical Services Public Co. Ltd. NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR recorded 3.61B in income tax expense. That works out to an effective tax rate of 18.59, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 19.42B, leaving 15.32B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR's stock has declined approximately 3.48% over the past 52 weeks. The 50-day moving average sits at 19.65, while the 200-day moving average is 19.32.

Over the twelve months ended June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR generated 111.80B in revenue and converted that into 15.32B in net income, yielding earnings per share of 0.99. EBITDA reached 26.78B, while operating income came in at 19.49B.

As of June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR holds 4.71B in cash and equivalents against 19.08B in total debt, resulting in a net debt position of 7.09B. Total book value stands at 103.25B, with working capital of -3.87B providing operational flexibility.

Bangkok Dusit Medical Services Public Co. Ltd. NVDR produced 21.56B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -9.65B in capital expenditures, free cash flow totaled 11.92B - equivalent to 0.75 per share.

Over the twelve months ended June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR posted a gross margin of 35.40, reflecting its pricing power and cost economics. The operating margin of 17.44 and net profit margin of 13.70 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR paid dividends of 0.35 per share. The dividend payout ratio of 34.10 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.89, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.63, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bangkok Dusit Medical Services Public Co. Ltd. NVDR shareholders.

Bangkok Dusit Medical Services Public Co. Ltd. NVDR's most recent stock split took place on April 29, 2014 with a 1:10 split ratio.

As of June 30, 2026, Bangkok Dusit Medical Services Public Co. Ltd. NVDR has an Altman Z-Score of 5.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.